| July 25, 2024 |
Timely Disclosure Information
|
StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Temporary Employees and External Collaborator
|
| July 8, 2024 |
Timely Disclosure Information
|
StemRIM Announces Patent Registration in Japan for Stem Cell & Gene Therapy for Dystrophic Epidermolysis Bullosa
|
| July 1, 2024 |
Timely Disclosure Information
|
Notice of Extraordinary General Meeting of Shareholders
|
| June 17, 2024 |
Timely Disclosure Information
|
StemRIM Announces Patent Registration (Australia) for the HMGB1 Fragment Peptide Redasemtide as an Additional Therapeutic Indication
|
| June 12, 2024 |
Financial Results
|
Non-consolidated Financial Results for the Nine Months Ended April 30, 2024 [Japanese GAAP]
|
| May 8, 2024 |
Timely Disclosure Information
|
StemRIM Announces Setting the Record Date for Extraordinary General Meeting of Shareholders, and Reduction of Capital Stock (Capital Decrease)
|
| March 21, 2024 |
Timely Disclosure Information
|
StemRIM Announces Symposium on “Regeneration-Induced Pluripotent Stem Cells” at the 23rd Congress of the Japanese Society for Regenerative Medicine
|
| March 15, 2024 |
Presentation Materials
|
Presentation Materials for Six Months Ended January 31 2024
|
| March 13, 2024 |
Financial Results
|
Non-consolidated Financial Results for the Six Months Ended January 31, 2024[Japanese GAAP]
|
| March 13, 2024 |
Timely Disclosure Information
|
StemRIM Announces Initiation of Phase 2 Clinical Trial for Redasemtide in Ischemic Cardiomyopathy
|
| February 29, 2024 |
Timely Disclosure Information
|
StemRIM Announces Fixed Details of the Issuance of Stock Options to External Collaborators
|
| February 15, 2024 |
Timely Disclosure Information
|
StemRIM Announces Patent Registration (Japan) for Redasemtide as an Additional Therapeutic Indication of Traumatic Brain Injury
|
| February 14, 2024 |
Timely Disclosure Information
|
StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to External Collaborators
|
| January 31, 2024 |
Timely Disclosure Information
|
StemRIM Announces Patent Registration (Russia) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication of Cartilage Disorders (Traumatic Cartilage Deficiency Syndrome, Osteoarthritis, Disseverance Osteochondritis, etc.)
|
| December 28, 2023 |
Timely Disclosure Information
|
StemRIM Announces Fixed Details of the Issuance of Stock Options to External Collaborator
|
